Ataibeckley Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated September 11, 2026, announces the consummation of a merger between Ataibeckley Inc. (the "Company") and Eli Lilly and Company ("Parent"). The Company has become a wholly owned subsidiary of Eli Lilly. The transaction was originally announced on July 16, 2026, and closed on the date of this report.
Key Financial Metrics and Transaction Terms
This filing details the terms of the acquisition rather than standard operating financial metrics (revenue, profit, cash flow), which are not provided in this document.
- Cash Consideration: Shareholders received $6.75 per share in cash.
- Contingent Value Rights (CVRs): Shareholders received one CVR per share, representing the right to receive up to an additional $2.50 per share upon achieving specific milestones.
- Total Potential Consideration: Up to $9.25 per share ($6.75 cash + $2.50 CVR).
- Equity Awards: In-the-money stock options and RSUs were cashed out based on the $6.75 closing amount and converted to CVRs. Out-of-the-money options were cancelled for no consideration.
Material Changes Versus Prior Period
The most significant change is the change in control and the cessation of the Company as an independent public entity.
- Delisting: The Company's common stock (Symbol: ATAI) has been delisted from The Nasdaq Stock Market and deregistered under Section 12(b) of the Exchange Act.
- Corporate Status: The Company is now a wholly owned subsidiary of Eli Lilly and Company.
- Leadership Change: The entire Board of Directors and executive officers resigned. New directors and officers appointed by Eli Lilly (including Jonathan R. Haug as President) assumed control.
- Reporting Obligations: The Company intends to file Form 15 to terminate its registration and suspend reporting obligations under Sections 13 and 15(d) of the Exchange Act.
Outlook, Milestones, and Risks
Future value for former shareholders depends entirely on the performance of specific clinical and regulatory milestones tied to the CVRs. The CVRs are non-transferable, unregistered, and carry no voting or dividend rights.
CVR Milestone Schedule
- Up to $1.00 per share: Initiation of a Phase 3 clinical trial of VLS-01 prior to the 4th anniversary of the Closing Date.
- Up to $0.50 per share: U.S. regulatory approval and DEA rescheduling of BPL-003 prior to the 5th anniversary of the Closing Date.
- Up to $1.00 per share: U.S. regulatory approval and DEA rescheduling of VLS-01 prior to the 7th anniversary of the Closing Date.
Unusual Items: A retention bonus of $194,000 was approved for Gerd Kochendoerfer, payable following the Closing Date subject to continued employment.
Investor Verification Checklist
- Verify the receipt of the $6.75 per share cash payment and the issuance of CVRs.
- Confirm the status of the CVR Agreement and the specific definitions of the clinical milestones for VLS-01 and BPL-003.
- Check for the filing of Form 25 (delisting) and Form 15 (termination of reporting) with the SEC.
- Review the treatment of any outstanding equity awards (options/RSUs) to ensure correct cash-out calculations and CVR allocations.
- Monitor future press releases from Eli Lilly regarding the progress of the VLS-01 and BPL-003 programs to assess CVR payout potential.